One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more mature data: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUAnzu-cel maintains a favorable tolerability profile in metastatic uveal melanomaAnti-tumor activity observed across metastases throughout the body, including liver lesions, and in patients who rece ...